Navigation Links
Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/14/2008

ISELIN, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 5:15 PM Central Europe Daylight Time (GMT +2:00, or 11:15 AM Eastern Daylight Time). The conference is taking place May 19-20, 2008 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

In the presentation, Mr. Neill will provide an update on the Company's business and product pipeline. A webcast of the presentation will be available and archived for 90 days after the conference at http://www.wsw.com/webcast/rrshq13/pars. For additional information on this conference please visit http://www.rodmanandrenshaw.com/conferences?id=18.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoimmune disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with IBS. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the NSAID diclofenac topically in patients suffering from osteoarthr
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... N.J. , March 30, 2015  Naldemedine, ... under development by Shionogi & Co., Ltd., met ... III study (COMPOSE I) for the treatment of ... non-cancer pain receiving opioid therapy. Study results showed ... statistically significantly improved the frequency of spontaneous bowel ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 /PRNewswire/ ... two studies in which Caris Molecular Intelligence®, the ... molecular similarities and differences between several rare and ... treatment strategies that have the potential to improve ... Poster Session B at the Society of Gynecologic ...
(Date:3/29/2015)... As a symbol of its commitment ... pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to announce ... Race Team for the 2015 race season. Success on ... a strong sense of precision and attention to detail. ... in the quality control testing laboratory. Sponsorship of the ...
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... Conn. Two major steps toward putting quantum computers into ... a qubit onto wires and transmitting the signal to a ... team of scientists at Yale. The accomplishments are reported in ... on which it is highlighted as the cover along with ...
... (Nasdaq: PRXL ), a leading global ... of the acquisition,of Taiwan-based APEX International Clinical ... release. In conjunction with the acquisition and ... its forward-looking,financial guidance for the first quarter ...
... 26 Today at the Clinton Global,Initiative ... a,ground-breaking vaccine to eliminate epidemic meningitis in ... developed by the Meningitis,Vaccine Project, a partnership ... produced by Serum Institute of India Limited ...
Cached Biology Technology:Yale scientists make 2 giant steps in advancement of quantum computing 2Yale scientists make 2 giant steps in advancement of quantum computing 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 4PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 2PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 3
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/10/2015)... YORK , March 10, 2015  Continuing its ... the Unexpected, Hammacher Schlemmer introduces The Eye Scanning ... identity before granting access to secure websites or sensitive ... to verify travelers at international borders, the device has ... distinctive pattern points of the iris, converting them into ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... deploy a deflector shield to evade enemy attack, tumor cells ... their own to fend off treatments aimed at killing them. ... their armor. , The cells churn out an enzyme that ... damage from radiation or chemotherapy and promotes tumor cell survival. ...
... of antibodies against the Epstein-Barr virus, the virus that ... develop multiple sclerosis 15 to 20 years later, according ... in the June 2006 print issue of Archives of ... long suspected that external factors may influence the risk ...
... new way of looking beneath the ocean surface that ... , A remote sensor system developed by Associate Professor ... MIT, Northeastern University and the Naval Research Laboratory, allows ... well as small schools, over a 10,000-square-kilometer area - ...
Cached Biology News:Molecular force field helps cancer cells defend against attack 2Molecular force field helps cancer cells defend against attack 3Big hips, big belly? It's in your genes, Joslin-led study shows 2One fish, two fish: New MIT sensor improves fish counts 2
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Corticoliberin...
...
Biology Products: